Health
Phico Therapeutics awarded up to $18.2 million USD (c.£13.2 million GBP) CARB-X funding to advance SASPject antibacterial therapy through Phase 1 clinical trials – News-Medical.net
Phico Therapeutics has been awarded a grant of up to $18.2 million USD to tackle the global rising threat of drug-resistant bacteria.
Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to $18.2 million USD (circa. £13.2 million GBP) from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
Phico Therapeutics…
-
Noosa News17 hours agoTeenage boy crashes into Ipswich home, left fighting for life in hospital
-
General22 hours agoShored against our ruins
-
General23 hours agoUN special envoy Julie Bishop makes first trip to Myanmar after earthquake
-
General21 hours agoNZ PM wants united trade bloc-EU response to tariffs